Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction

Circulation

Volumn 106, Issue 12, 2002, Pages 1447-1452

  Plenge, Julie K ^a   Hernandez, Teri L ^a   Weil, Kathleen M ^a   Poirier, Paul ^a   Grunwald, Gary K ^a   Marcovina, Santica M ^a   Eckel, Robert H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

C reactive protein; Fibrinogen; Inflammation; Lipoproteins

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIAS; KINETICS; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 0037126043     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000029743.68247.31     Document Type: Article

References (35)

1. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
2. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
3. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
4. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators
5. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
6. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
7. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
8. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)
9. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans
10. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)
11. Random-effects models for longitudinal data
12. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
13. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
14. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
15. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
16. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention
17. Statins and the acute-phase response
18. Acute-phase proteins and other systemic responses to inflammation
19. Risk factors for atherosclerotic disease
20. Inflammation and atherosclerosis
21. Chronic systemic inflammation in overweight and obese adults
22. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo
23. Adipose tissue as an endocrine and paracrine organ
24. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia
25. Lipoprotein(a) levels and risk of coronary heart disease in men: The Lipid Research Clinics Coronary Primary Prevention Trial
26. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
27. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: A prospective study
28. Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin
29. Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia
30. Effect of simvastatin on Lp(a) concentrations
31. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators
32. Withdrawal of statins increases event rates in patients with acute coronary syndromes
33. The value of C-reactive protein measurement in rheumatoid arthritis